

WATSON PHARMACEUTICALS INC  
Form 8-K  
August 03, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934**

**August 3, 2004**

Date of Report (Date of earliest event reported)

**WATSON PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other Jurisdiction  
of Incorporation)

**0-20045**

(Commission File Number)

**95-3872914**

(IRS Employer  
Identification Number)

**311 Bonnie Circle**

**Corona, California**

(Address of principal executive  
offices)

**92880**

(Zip Code)

**(951) 493-5300**

(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) Exhibits The following exhibit is furnished as part of this Report:

<b>Exhibit Number</b>	<b>Description</b>
99.1	News Release titled Watson Pharmaceuticals Reports Second Quarter 2004 Results dated August 3, 2004.

**Item 12. Results of Operations and Financial Condition.**

On August 3, 2004, Watson Pharmaceuticals, Inc. (the Company) issued a news release announcing its financial results for the second quarter ended June 30, 2004. A copy of the Company's news release is attached hereto as Exhibit 99.1.

In its news release, the Company included future non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission, with respect to the third quarter of 2004 and the full year of 2004 forecasts. The Company believes that its inclusion of non-GAAP financial measures provides useful supplementary information to investors in evaluating the Company's performance and trends. The Company uses both GAAP financial measures and the disclosed non-GAAP financial measures internally to evaluate and manage the Company's operations and to better understand its business.

The information being furnished under this Item 12 shall not be deemed filed for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities and Exchange Act of 1934, except as shall be expressly set forth by specific reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 3, 2004.

WATSON PHARMACEUTICALS, INC.

By:            /s/Charles P. Slacik  
                 Charles P. Slacik  
                 Executive Vice President and  
                 Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	News Release titled Watson Pharmaceuticals Reports Second Quarter 2004 Results dated August 3, 2004.